Now showing items 1-4 of 4

    • Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. 

      O'Leary, B; Hrebien, S; Morden, JP; Beaney, M; Fribbens, C; Huang, X; Liu, Y; Bartlett, CH; Koehler, M; Cristofanilli, M; Garcia-Murillas, I; Bliss, JM; Turner, NC (2018-03-01)
      CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA ...
    • Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. 

      Fribbens, C; O'Leary, B; Kilburn, L; Hrebien, S; Garcia-Murillas, I; Beaney, M; Cristofanilli, M; Andre, F; Loi, S; Loibl, S; Jiang, J; Bartlett, CH; Koehler, M; Dowsett, M; Bliss, JM; Johnston, SR; Turner, NC (2016-09)
      ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that represent ...
    • Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. 

      Fribbens, C; Garcia Murillas, I; Beaney, M; Hrebien, S; O'Leary, B; Kilburn, L; Howarth, K; Epstein, M; Green, E; Rosenfeld, N; Ring, A; Johnston, S; Turner, N (2018-01-01)
      Background: Selection of resistance mutations may play a major role in the development of endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase ...
    • Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. 

      Mansukhani, S; Barber, LJ; Kleftogiannis, D; Moorcraft, SY; Davidson, M; Woolston, A; Proszek, PZ; Griffiths, B; Fenwick, K; Herman, B; Matthews, N; O'Leary, B; Hulkki, S; Gonzalez De Castro, D; Patel, A; Wotherspoon, A; Okachi, A; Rana, I; Begum, R; Davies, MN; Powles, T; von Loga, K; Hubank, M; Turner, N; Watkins, D; Chau, I; Cunningham, D; Lise, S; Starling, N; Gerlinger, M (2018-11)
      BACKGROUND: Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome landscapes, but highly sensitive and specific technologies are necessary to accurately detect mutations with often low variant frequencies. ...